Tomimori Yoshiaki, Kawakami Yuko, McCausland Megan M, Ando Tomoaki, Koriazova Lilia, Kato Shinichiro, Kawakami Toshiaki, Crotty Shane
Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA.
Antivir Ther. 2011;16(1):67-75. doi: 10.3851/IMP1717.
Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema).
Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum.
Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions.
These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
种痘性湿疹是与天花疫苗接种(痘苗病毒)相关的最常见的严重病理状况,在有特应性皮炎(特应性湿疹)既往史的个体中发生率很高。
开发了能够中和痘苗病毒的单克隆抗体抗-H3和抗-B5,作为治疗人类种痘性湿疹的一种潜在疗法。
使用种痘性湿疹的小动物模型,我们证明鼠源和全人源单克隆抗体均能有效限制种痘性湿疹疾病,缩短疾病进程以及糜烂性病毒性皮肤损伤的严重程度。
这些中和抗体可能有效减轻或消除种痘性湿疹患者的临床疾病或天花疫苗的其他严重副作用。